Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models

MLA

Fu-Tien Liao, et al. “Abstract P1-13-17: Hyperactivation of the EGFR Pathway Is Associated with Resistance to Tucatinib in HER2-Positive Breast Cancer Models.” Cancer Research, vol. 83, Mar. 2023, pp. P1-13. EBSCOhost, https://doi.org/10.1158/1538-7445.sabcs22-p1-13-17.

APA

Fu-Tien Liao, Tia Gordon, Chia Chia Liu, Pier Selenica, Yingjie Zhu, Juber Patel, Sarmistha Nanda, Lanfang Qin, Xiaoyong Fu, Andrea Gazzo, Antonio Marra, Juan Blanco-Heredia, Britta Weigelt, Jorge Reis-Filho, C. Kent Osborne, Mothaffar Rimawi, Rachel Schiff, & Jamunarani Veeraraghavan. (2023). Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models. Cancer Research, 83, P1-13. https://doi.org/10.1158/1538-7445.sabcs22-p1-13-17

Chicago

Fu-Tien Liao, Tia Gordon, Chia Chia Liu, Pier Selenica, Yingjie Zhu, Juber Patel, Sarmistha Nanda, et al. 2023. “Abstract P1-13-17: Hyperactivation of the EGFR Pathway Is Associated with Resistance to Tucatinib in HER2-Positive Breast Cancer Models.” Cancer Research 83 (March): P1-13. doi:10.1158/1538-7445.sabcs22-p1-13-17.